Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
79.43(c) 78.53(c) 77.56(c) 73.92(c) 73.19(c) Last
9 699 151 13 189 354 11 957 488 32 615 901 31 267 836 Volume
-0.51% -1.13% -1.24% -4.69% -0.99% Change
More quotes
Financials (USD)
Sales 2019 44 422 M
EBIT 2019 14 946 M
Net income 2019 10 013 M
Debt 2019 17 055 M
Yield 2019 3,01%
Sales 2020 46 996 M
EBIT 2020 16 349 M
Net income 2020 11 624 M
Debt 2020 14 810 M
Yield 2020 3,11%
P/E ratio 2019 18,56
P/E ratio 2020 15,73
EV / Sales2019 4,64x
EV / Sales2020 4,34x
Capitalization 189 B
More Financials
Company
Merck and Company specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory,... 
Sector
Pharmaceuticals
Calendar
04/25Presentation
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
04/17MERCK AND : on Pace for Largest Percent Decrease in Over a Year -- Data Talk
DJ
04/17AGILENT TECHNOLOGIES : Receives an Expanded FDA Approval for its Companion Diagn..
AQ
04/16MERCK AND : Keytruda continues its lung cancer land grab with another FDA nod
AQ
04/13MERCK AND : Results of Phase 3 Trial Evaluating Merck's ZERBAXA® (ceftolozane an..
BU
04/11MERCK AND : FDA Approves Expanded Monotherapy Label for Merck's KEYTRUDA® (pembr..
BU
04/11MERCK AND : Says FDA Approves Keytruda for First-Line Treatment of Some Lung Can..
DJ
04/11CEO TALK : Aytu BioScience (NasdaqCM: AYTU) CEO Discusses Past, Present, and Fut..
AQ
04/10MERCK AND : LYNPARZA® (olaparib) Approved in EU for the Treatment of Germline BR..
BU
04/10ASTRAZENECA : Lynparza Approved in EU to Treat a Form of Breast Cancer
DJ
04/10ASTRAZENECA : Lynparza approved in EU for the treatment of germline BRCA-mutated..
AQ
More news
Analyst Recommendations on MERCK AND COMPANY
More recommendations
Sector news : Pharmaceuticals - NEC
04/19TEVA PHARMACEUTICAL INDUSTRIES : Pharma Gets FDA Approval to Market Generic Nasa..
DJ
04/18Pfizer, Lilly Release Top-Line Results From Phase 3 Study of Tanezumab for Os..
DJ
04/18Pfizer, Johnson & Johnson Weigh on Pharmaceutical ETFs
DJ
04/17ACREAGE : Canopy Growth nearing deal to buy U.S.-based pot company Acreage Holdi..
RE
04/17Roche Raises 2019 Sales View After 1Q Sales Beat
DJ
More sector news : Pharmaceuticals - NEC
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 87,4 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-4.21%189 055
JOHNSON & JOHNSON6.56%366 184
ROCHE HOLDING LTD.8.22%224 627
PFIZER-9.78%218 630
NOVARTIS3.69%194 472
ELI LILLY AND COMPANY-0.45%119 326